Table 2.

Summary of preclinical studies of iCasp9 T cells co-expressing different CARs.

CAR-T Cells	Cancer Type	Time after Suicide Induction	Percentage of Eradicated CAR-T Cells	Reference
iCasp9-IL15-CD19CAR	B-cell malignancies	24 h	>95.0%	[35]
iCasp9-CD20CAR-Δ19	B-cell malignancies	24 h 72 h	90.0% 98.0%	[36]
iCasp9-CD20CAR-ΔNCFR	B-cell malignancies	48 h	>99.0%	[37]
iCasp9-CD33CAR-Δ19	AML	N/A	76.4%	[38]
iCasp9-IL1RAPCAR-Δ19	CML	N/A	87.0%	[39]